Clinical Focus >

2022 , Vol. 37 >Issue 10: 905 - 911

DOI: https://doi.org/10.3969/j.issn.1004-583X.2022.10.004

Effect of subclinical hypothyroidism on prognosis of patients with chronic systolic heart failure: A meta-analysis

  • Xiuxiu Zuo ,
  • Tianhua Hou ,
  • Hongxiang Wang
Expand
  • 1. Chengde Medical University, Chengde 067000, China
    2. Department of Cardiology, Chengde Central Hospital, Chengde 067000, China

Received date: 2022-06-17

  Online published: 2022-11-26

Fold

Abstract

Objective To systematically evaluate the effect of subclinical hypothyroidism (SCH) on prognosis of patients with chronic systolic heart failure (CSHF). Methods A computer search was conducted in Web of Science, Cochrane Library, Chinese Biomedical Database (CBM), China National Knowledge Internet (CNKI), Wanfang, VIP database up to May 2022. The literatures regarding SCH-related prognosis of CSHF patients were extracted based on predefined inclusion/exclusion criteria. The Newcastle-Ottawa scale (NOS) was performed to evaluate the relevant data extracted, a Meta-analysis was conducted using STATA 12.0 statistical software, and the hazard ratio (HR) and its 95% confidence interval (95%CI) were used as the effect quantities. Results Eligible 9 literatures representing 21 723 CSHF patients (hypothyroidism in 1 225; euthyroidism in 19 120) were included in the meta-analysis. Meta-analysis results showed that all-cause mortality (HR=1.58, 95%CI: 1.30-1.92), cardiovascular adverse event and (or) re-hospitalization (HR=1.42, 95%CI: 1.16-1.73) were risk factors for hypothyroidism as compared to euthyroidism. SCH was associated with poor prognosis of CSHF patients in subgroup analysis. The less than 24 months follow-ups were most strongly associated with all-cause mortality (HR=2.50), Asian CSHF patients were most strongly associated with cardiovascular adverse event and (or) re-hospitalization(HR=1.59). Conclusion SCH might be associated with the risk factors for all-cause mortality, cardiovascular events, and/or hospitalization of CHF patients.

Key words： hypothyroidism; systolic heart failure; prognosis; meta-analysis

Cite this article

Xiuxiu Zuo , Tianhua Hou , Hongxiang Wang . Effect of subclinical hypothyroidism on prognosis of patients with chronic systolic heart failure: A meta-analysis[J]. Clinical Focus, 2022 , 37(10) : 905 -911 . DOI: 10.3969/j.issn.1004-583X.2022.10.004

References

[1] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America[J]. Circulation, 2017, 136(6):e137-e161.
[2] Ning N, Gao D, Triggiani V, et al. Prognostic role of hypothyroidism in heart failure: A meta-analysis[J]. Medicine (Baltimore), 2015, 94(30):e1159.
[3] Bielecka-Dabrowa A, Godoy B, Suzuki T, et al. Subclinical hypothyroidism and the development of heart failure: An overview of risk and effects on cardiac function[J]. Clin Res Cardiol, 2019, 108(3):225-233.
[4] 杨宜恒, 郑振中. 亚临床甲状腺功能减退对心力衰竭患者预后影响的Meta分析[J]. 实用心脑肺血管病杂志, 2021, 29(5):70-74.
[5] Yang G, Wang Y, Ma A, et al. Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction[J]. BMC Cardiovasc Disord, 2019, 19(1):83.
[6] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9):603-605.
[7] Iacoviello M, Guida P, Guastamacchia E, et al. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients[J]. Curr Pharm Des, 2008, 14(26):2686-2692.
[8] Sato Y, Yoshihisa A, Kimishima Y, et al. Subclinical hypothyroidism is associated with adverse prognosis in heart failure patients[J]. Can J Cardiol, 2018, 34(1):80-87.
[9] Kannan L, Shaw PA, Morley MP, et al. Thyroid dysfunction in heart failure and cardiovascular outcomes[J]. Circ Heart Fail, 2018, 11(12):e005266.
[10] Frey A, Kroiss M, Berliner D, et al. Prognostic impact of subclinical thyroid dysfunction in heart failure[J]. Int J Cardiol, 2013, 168(1):300-305.
[11] Wang W, Guan H, Gerdes AM, et al. Thyroid status, cardiac function, and mortality in patients with idiopathic dilated cardiomyopathy[J]. J ClinEndocrinol Metab, 2015, 100(8):3210-3218.
[12] Li X, Yang X, Wang Y, et al. The prevalence and prognostic effects of subclinical thyroid dysfunction in dilated cardiomyopathy patients: A single-center cohort study[J]. J Card Fail, 2014, 20(7):506-512.
[13] 刘凯, 陈英, 郑杨, 等. 亚临床甲状腺功能减退对老年心力衰竭病人预后的影响[J]. 实用老年医学, 2019, 33(11):1108-1112.
[14] Rhee CM, Curhan GC, Alexander EK, et al. Subclinical hypothyroidism and survival: The effects of heart failure and race[J]. J Clin Endocrinol Metab, 2013, 98(6):2326-2336.
[15] Shuichi K, Shohei K, Hiroo S, et al. Subclinical hypothyroidism is a useful predictor of adverse events in heart failure patients with reduced left ventricular ejection fraction[J]. J CARD FAIL, 2015, 21(10):S187.
[16] Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: The Whickham survey[J]. Clin Endocrinol (Oxf), 1977, 7(6):481-493.
[17] Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study[J]. Arch Intern Med, 2000, 160(4):526-534.
[18] Kannan L, Shaw PA, Morley MP, et al. Thyroid dysfunction in heart failure and cardiovascular outcomes[J]. Circ Heart Fail, 2018, 11(12):e005266.
[19] Lam CS, Lyass A, Kraigher-Krainer E, et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community[J]. Circulation, 2011, 124(1):24-30.
[20] Biondi B. Mechanisms in endocrinology: Heart failure and thyroid dysfunction[J]. Eur J Endocrinol, 2012, 167(5):609-618.
[21] Martínez-Sellés M, García Robles JA, Prieto L, et al. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function[J]. Rev Esp Cardiol, 2002, 55(6):579-586.
[22] Ilic S, Tadic M, Ivanovic B, et al. Left and right ventricular structure and function in subclinical hypothyroidism: The effects of one-year levothyroxine treatment[J]. Med Sci Monit, 2013, 19:960-968.
[23] Tadic M, Ilic S, Kostic N, et al. Subclinical hypothyroidism and left ventricular mechanics: A three-dimensional speckle tracking study[J]. J Clin Endocrinol Metab, 2014, 99(1):307-314.
[24] Mousa S, Hemeda A, Ghorab H, et al. Arterial wall stiffness and the risk of atherosclerosis in egyptian patients with overt and subclinical hypothyroidism[J]. Endocr Pract, 2020, 26(2):161-166.
[25] Saif A, Mousa S, Assem M, et al. Endothelial dysfunction and the risk of atherosclerosis in overt and subclinical hypothyroidism[J]. Endocr Connect, 2018, 7(10):1075-1080.
[26] Swaid B, Kheiri B, Sundus S, et al. The effect of levothyroxine treatment in individuals with subclinical hypothyroidism on surrogate markers of atherosclerosis: A meta-analysis of randomized controlled trials[J]. J Community Hosp Intern Med Perspect, 2019, 9(4):305-309.
[27] Sengupta S, Jaseem T, Ambalavanan J, et al. Homeostatic model assessment-insulin resistance (HOMA-IR 2) in mild subclinical hypothyroid subjects[J]. Indian J Clin Biochem, 2018, 33:214-217.
[28] Treister-Goltzman Y, Yarza S, Peleg R. Lipid profile in mild subclinical hypothyroidism: Systematic review and meta-analysis[J]. Minerva Endocrinol (Torino), 2021, 46(4):428-440.
[29] Hueston WJ, Pearson WS. Subclinical hypothyroidism and the risk of hypercholesterolemia[J]. Ann Fam Med, 2004, 2(4):351-355.
[30] Jayasingh IA, Puthuran P. Subclinical hypothyroidism and the risk of hypercholesterolemia[J]. J Family Med Prim Care, 2016, 5(4):809-816.
[31] Papadopoulou AM, Bakogiannis N, Skrapari I, et al. Thyroid dysfunction and atherosclerosis: A systematic review[J]. In Vivo, 2020, 34(6):3127-3136.
Options
Outlines

/

〈 〉